Challenges and Opportunities in Cancer Drug Resistance
Year: 2020
Type: review
Source: Chemical Reviews
Institutions: AstraZeneca (United Kingdom), AstraZeneca (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: AstraZeneca
OpenAlex ID: W3043934334
